PFE

Pfizer Inc.
CAPPED RATING

Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer Inc. (PFE) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 41.3
EV / EBITDA N/A
Rev Growth YoY -0.4%
Gross Margin 74.9%
Price Return 3M 9.1%
Price Return 12M 19.1%
Catalyst Signal +0.01
Market Cap $164.7B
TTM Revenue $63.6B
Price / Sales 2.6
ROE 4.5%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.7) D+ (1.8) B+ (3.8) B+ (3.6) D+ (1.5) C+ (2.7)
2026-11-09 B- (2.9) D+ (1.8) B+ (3.8) B (3.4) D+ (1.5) C+ (2.7)
2026-11-06 B- (2.9) D+ (1.8) B+ (3.8) B+ (3.6) D+ (1.6) C+ (2.7)
2026-11-04 B- (2.9) D+ (1.8) B+ (3.8) B (3.4) D+ (1.6) C+ (2.7)
2026-11-03 B- (2.9) D+ (1.8) B+ (3.8) B (3.4) D+ (1.6) C+ (2.7)
Page 1 of 14
…